Brain lesions in tuberous sclerosis complex. Review

Folia Neuropathologica

Volumn 48, Issue 3, 2010, Pages 139-149

  Grajkowska, Wiesława ^a   Kotulska, Katarzyna ^a   Jurkiewicz, Elzbieta ^a   Matyja, Ewa ^b  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Cortical tubers; Hamartin; mTOR; Rapamycin therapy; SEGA; SEN; TSC; Tuberin

Indexed keywords

HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; TUBERIN;

ASTROCYTOMA; AUTOSOMAL DOMINANT DISORDER; BRAIN DAMAGE; GENE MUTATION; HAMARTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MITOSIS RATE; NEUROIMAGING; REVIEW; SIGNAL TRANSDUCTION; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE;

EID: 77957670573     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Ahlsén G, Gillberg IC, Lindblom R, Gilberg C. Tuberous sclerosis in Western Sweden. A population study of cases with early childhood onset. Arch Neurol 1994; 51: 76-81.
2. Baskin HJ Jr. The pathogenesis and imaging of the tuberous sclerosis complex. Pediatr Radiol 2008; 38: 936-952.
3. Boer K, Jansen F, Nellist M, Redeker S, van den Ouweland AM, Spliet WG, van Nieuwenhuizen O, Troost D. Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Epilepsy Res 2008; 78: 7-21.
4. Braffman BH, Bilaniuk LT, Naidich TP, Altman NR, Post MJ, Quencer RM, Zimmerman RA, Brody BA. MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology 1992; 183: 227-238.
5. Chan JA, Zhang H, Roberts PS, Jozwiak S, Grajkowska W, Lewin- Kowalik J, Kotulska K, Kwiatkowski DJ. Pathogenesis of tuberous clerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leades to mTOR activation. J Neuropathol Exp Neurol 2004; 63: 1236-1242.
6. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006; 355: 1345-1356.
7. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372: 657-668.
8. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001; 68: 64-80.
9. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490-498.
10. Freilinger A, Rosner M, Krupitza G, Nishino M, Lubec G, Korsmeyer SJ, Hengstschläger M. Tuberin activates the proapoptotic molecule BAD. Oncogene 2006; 25: 6467-6479.
11. Grajkowska W, Kotulska K, Matyja E, Larysz-Brysz M, Mandera M, Roszkowski M, Domańska-Pakieła D, Lewik-Kowalik J, Jóźwiak S. Expression of tuberin and hamartin In tuberous sclerosis complex- associated and sporadic cortical dyspalsia of Taylor's balloon cell type. Folia Neuropathol 2008; 46: 43-48.
12. Gyure KA, Prayson RA. Subependymal giant cell astrocytoma: a clinicopathologic study with HMB45 and MIB-1 immunohistochemical analysis. Mod Pathol 1997: 10: 313-317.
13. Jozwiak J, Grajkowska W, Kotulska K, Jozwiak S, Zalewski W, Zajaczkowska A, Roszkowski M, Slupianek A, Wlodarski P. Brain tumor formation in tuberous sclerosis depends on Erk activation. Neuromolecular Med 2007; 9: 117-127.
14. Jóźwiak S, Migone N, Ruggieri M. The Tuberous Sclerosis Complex. In: Ruggieri M, Castroviejo IP, DiRocco C (eds.). Neurocutaneous Disorders. Springer, Wien, NewYork 2008; pp. 181-227.
15. Jozwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol 2000; 15: 652-659.
16. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584: 1287-1295.
17. Jurkiewicz E, Jozwiak S, Bekiesinska-Figatowska M, Pakula- Kosciesza I, Walecki J. Cyst-like cortical tubers in patients with tuberous sclerosis complex: MR imaging with the FLAIR sequence. Pediatr Radiol 2006; 36: 498-501.
18. Kwiatkowski DJ, Whittemore VH, Thiele EA. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley VCH, Weinheim 2010.
19. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2005; 14: 251-258.
20. Lam C, Bouffet E, Tabori U, Mabbott D, Taylor M, Bartels U. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer 2009; 54: 476-479.
21. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009; 15: 1612-1622.
22. Lee-Jones L, Aligianis I, Davies PA, Puga A, Stemmer-Rachamimov A, Ramesh V, Sampson JR. Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2. Genes Chromosomes Cancer 2004; 41: 80-85.
23. Ljungberg MC, Sunnen CN, Lugo JN, Anderson AE, D'Arcangelo G. Rapamycin suppresses seizures and neuronal hyphertrophy in a mouse model of cortical dysplasia. Dis Model Mech 2009; 2: 389-398.
24. Mizuguchi M, Takashima S. Neuropthology of tuberous sclerosis complex. Brain Dev 2001; 23: 508-515.
25. Nie D, Di Nardo A, Han JM, Baharanyi H, Kramvis I, Huynh T, Dabora S, Codeluppi S, Pandolfi PP, Pasquale EB, Sahin M. Tsc2- Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci 2010; 13: 163-172.
26. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13: 624-628.
27. Rott HD, Lemcke B, Zenker M, Huk W, Horst J, Mayer K. Cyst-like cerebral lesions in tuberous sclerosis. Am J Med Genet 2002; 111: 435-439.
28. Talos DM, Black PM, Jensen FE. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann Neurol 2008; 63: 454-465.
29. Tyburczy ME, Kotulska K, Pokarowski, P Mieczkowski J, Kuchar- ska J, Grajkowska W, Roszkowski M, Jozwiak S, Kaminska B. Novel Proteins Regulated by mTOR in Subependymal Giant Cell Astrocytomas of Patients with Tuberous Sclerosis Complex and New Therapeutic Implications. Am J Pathol 2010; 176: 1878-1890.
30. Vinters HV, Miyata H. Neuropathologic features of tuberous sclerosis. In: McLendon RE, Rosenblum MK, Bigner DD (eds.). Russel and Rubinsten's Pathology of Tumors of the Nervous System. 7th ed. Hodder Arnold Publication, London 2006; pp. 955-969.
31. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003, 5: 578-581.